Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0FZMIS
ADC Name
Anti-ApoD PBD
Synonyms
Anti-ApoD-PBD
   Click to Show/Hide
Drug Status
Investigative
Indication
In total 1 Indication(s)
Skin Photoaging [ICD11:EJ20]
Investigative
Antibody Name
Anti-ApoD Anti-ody
  Antibody Info 
Antigen Name
Apolipoprotein D (APOD)
  Antigen Info 
Payload Name
PBD dimer
  Payload Info 
Therapeutic Target
Human Deoxyribonucleic acid (hDNA)
  Target Info 
Linker Name
Undisclosed
General Information of The Activity Data Related to This ADC
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Tumor Growth Inhibition value (TGI) 
≈ 90
%
NHDF cells
Normal
Full List of Activity Data of This Antibody-drug Conjugate
Discovered Using Cell Line-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 90.00% Positive APOD expression (APOD +++/++)
Method Description
Male Bl6 mice, at 9 weeks old (young) or 80 weeks old (old), were intravenously treated with the vehicle alone or with anti-ApoD antibody and PBD-conjugated IgG with a cleavable linker, each at a concentration of 0.3 mg/kg and 3 mg/kg in a single dose.
In Vivo Model NHDF CDX model
In Vitro Model Normal NHDF cells Homo sapiens
References
Ref 1 New Senolysis Approach via Antibody-Drug Conjugate Targeting of the Senescent Cell Marker Apolipoprotein D for Skin Rejuvenation. Int J Mol Sci. 2023 Mar 20;24(6):5857. doi: 10.3390/ijms24065857.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.